The CrisBio technology from Cocoon opens new doors to the production of recombinant proteins for the health and cultured meat markets

Cocoon Bioscience is a young company that was born in September 2022 as a spin-off of the ALGENEX company, with the aim of producing recombinant proteins for life sciences and cultivated meat markets using our CrisBio® technology.

Traditionally, recombinant proteins are manufactured mainly through microbial fermentation with bacterial systems. While these systems are generally effective for most bioproduced proteins, we often encounter specific proteins that are difficult or impossible to produce due to complex post-translational modifications required; resulting in low overall activity and productivity. These proteins are often discarded due to their high complexity.

Our CrisBio® platform uses a totally different protein expression system, since it uses the pupae of the Trichoplusia NI moth as natural bioreactors for the production of enzymes and recombinant growth factors. The pupae are injected with Baculovirus and the required DNA sequence, generating the desired protein after 3-6 days.

This innovative and yet, very efficient system produces recombinant proteins at much lower costs than traditional systems and, at the same time, is capable of producing complex proteins that other expression systems are incapable of expressing.